Tumor-targeting photodynamic therapy based on folate-modified polydopamine nanoparticles

Area of Science:

• Biomedical Engineering
• Nanotechnology
• Oncology

Background:

• Photodynamic therapy (PDT) is a long-standing cancer treatment modality.
• Current photosensitizers face challenges with metabolic issues and off-target toxicity.
• There's a need for targeted delivery systems to improve PDT efficacy and safety.

Purpose of the Study:

• To develop a high-efficiency, high-specificity carrier for precise photosensitizer delivery to tumors.
• To overcome metabolic problems associated with current photosensitizers.
• To reduce systemic damage caused by off-target phototoxicity.

Main Methods:

• Synthesized a polydopamine (PDA)-based carrier modified with folic acid (FA) to target folate receptors.
• Loaded a cationic phthalocyanine-type photosensitizer (Pc) onto the PDA-FA carrier, creating PDA-FA-Pc nanomedicine.
• Evaluated in vitro antitumor effects and specificity, and in vivo tumor targeting and efficacy in human cancer-xenografted mice models.

Main Results:

• PDA-FA-Pc nanomedicine showed high stability in physiological conditions and specific photosensitizer release in acidic tumor microenvironments.
• Demonstrated significantly higher cellular uptake and phototoxicity in cancer cells compared to healthy cells.
• Exhibited excellent tumor-targeting properties in vivo and significantly suppressed tumor growth in mouse models.

Conclusions:

• PDA-FA-Pc nanomedicine represents a potent and specific anticancer agent for photodynamic therapy.
• This strategy effectively addresses metabolic and specificity challenges of clinical photosensitizers.
• The developed nanomedicine shows promise for improved cancer treatment outcomes.